Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Importance Sarcoidosis is an inflammatory granulomatous disease of unknown cause that
affects an estimated 2 to 160 people per 100 000 worldwide and can involve virtually any …

2022 ESC/ERS pulmonary hypertension guidelines incorporate changes and adaptations
focusing on clinical management https://bit. ly/3QtUvb4

Background The major reasons to treat sarcoidosis are to lower the morbidity and mortality
risk or to improve quality of life (QoL). The indication for treatment varies depending on …

Sarcoidosis-associated pulmonary hypertension (SAPH) is an important complication of
advanced sarcoidosis. Over the past few years, there have been several studies dealing …

Pulmonary hypertension (PH) associated with chronic lung disease (CLD) is both common
and underrecognised. The presence of PH in the setting of lung disease has been …

Sarcoidosis is a heterogeneous disease, which can affect virtually every body organ, even
though lungs and intra thoracic lymph nodes are almost universally affected. The presence …

Pulmonary hypertension is a progressive and often fatal cardiopulmonary condition
characterised by increased pulmonary arterial pressure, structural changes in the pulmonary …

Sarcoidosis is a sterile non-necrotizing granulomatous disease without known causes that
can involve multiple organs with a predilection for the lung and thoracic lymph nodes …

Sarcoidosis is a systemic granulomatous inflammatory disease of unknown etiology. It
affects the lungs in over 90% of patients yet extra-pulmonary and multi-organ involvement is …